First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented…

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1